Compare CXT & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXT | TWST |
|---|---|---|
| Founded | 1855 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | 1994 | 2018 |
| Metric | CXT | TWST |
|---|---|---|
| Price | $49.72 | $48.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $76.75 | $48.75 |
| AVG Volume (30 Days) | 785.0K | ★ 1.5M |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $3,374,900,000.00 | $376,572,000.00 |
| Revenue This Year | $6.36 | $18.89 |
| Revenue Next Year | $3.80 | $15.28 |
| P/E Ratio | $30.37 | ★ N/A |
| Revenue Growth | 6.13 | ★ 20.32 |
| 52 Week Low | $41.54 | $23.30 |
| 52 Week High | $69.00 | $57.88 |
| Indicator | CXT | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 55.47 |
| Support Level | $46.34 | $25.67 |
| Resistance Level | $57.62 | $57.88 |
| Average True Range (ATR) | 2.24 | 3.01 |
| MACD | -0.38 | -0.56 |
| Stochastic Oscillator | 1.47 | 22.97 |
Crane NXT Co is a industrial technology company that provides proprietary and trusted technology solutions to secure, detect, and authenticate what matters to its customers. It is a pioneer in proprietary micro-optics technology for securing physical products, and its sophisticated electronic equipment and associated software leverages proprietary core capabilities with detection and sensing technologies. The company operates in two segments which are Crane Payment Innovations (CPI) and Security and Authentication Technologies.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.